Menu

Speaking of Cancer Research

Notable quotes from this year’s annual meeting of the American Association for Cancer Research

Apr 5, 2017
Jef Akst

JEF AKST

“This is no time to undercut progress, for God’s sake. It’s no time to let up. It’s time to double down. It’s time we deliver on the promise of science and technology to extend and improve lives.”

—Former US Vice President Joe Biden

 

“Funding for cancer research isn’t something you can turn on and off like a faucet.”

Nancy Davidson, AACR President

 

“There has been a revolution in cancer research in the past decade. If I were to summarize that revolution in one sentence it would be: cancer results from the sequential accumulation of genomic alterations. . . . The challenge for all of us here to today is to achieve the next revolution, and that is to dramatically reduce deaths from cancer.”

Bert Vogelstein, Johns Hopkins Medicine

 

“At first blush, the problem of [cancer drug] resistance seems insurmountable. It’s multifactorial and heterogeneous. There can be multiple resistance mechanisms operating in a particular patient.”

Levi Garraway, Eli Lilly

 

“Early detection doesn’t have to be very early. . . . It takes years, perhaps decades, for a [malignancy] to evolve into a widely metastatic lesion, offering a huge window of opportunity to detect those cancers and intervene in the process.”

Vogelstein

 

“In our fight against cancer, we have to be unwilling to postpone for even a second. . . . Let’s keep it going, folks. This is no time to stop the momentum.”

Biden

November 2018

Intelligent Science

Wrapping our heads around human smarts

Marketplace

Sponsored Product Updates

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

Every minute counts when waiting for accurate diagnostic test results to guide critical care decisions, making today's clinical lab more important than ever. In fact, nearly 70 percent of critical care decisions are driven by a diagnostic test.

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC’s Genomics division announced it is transforming its branding under LGC, Biosearch Technologies, a unified portfolio brand integrating optimised genomic analysis technologies and tools to accelerate scientific outcomes.

DefiniGEN licenses CRISPR-Cas9 gene editing technology from Broad Institute to develop cell models for optimized metabolic disease drug development

DefiniGEN licenses CRISPR-Cas9 gene editing technology from Broad Institute to develop cell models for optimized metabolic disease drug development

DefiniGEN Ltd are pleased to announce the commercial licensing of CRISPR-Cas9 gene-editing technology from Broad Institute of MIT and Harvard in the USA, to develop human cell disease models to support preclinical metabolic disease therapeutic programmes.